Chronic intranigral administration of brain-derived neurotrophic factor produces striatal dopaminergic hypofunction in unlesioned adult rats and fails to attenuate the decline of striatal dopaminergic function following medial forebrain bundle transection

Neurotrophic factor therapy for nervous system degenerative diseases

The ability of neurotrophic factors to regulate developmental neuronal survival and adult nervous system plasticity suggests the use of these molecules to treat neurodegeneration associated with human diseases. Solid rationales exist for the use of NGF and neurotrophin-3 in the treatment of neuropathies of the peripheral sensory system, insulin-like growth factor and ciliary neurotrophic factor in motor neuron atrophy, and NGF in Alzheimer's disease. Growth factors have been identified for neurons affected in Parkinson's disease, Huntington's disease, and acute brain and spinal cord injury. Various strategies are actively pursued to deliver neurotrophic factors to the brain, and develop therapeutically useful molecules that mimic neurotrophic factor actions or stimulate their production or receptor mechanisms.

Clinical application of cell transplantation and neurotrophic factors in CNS disorders

Cell transplantation and administration of neurotrophic factors are now being explored as new therapeutic strategies to restore and preserve function in the diseased human central nervous system. Neural grafts show long-term survival and restore function in patients with Parkinson's disease, but the symptomatic relief needs to be increased. Cell transplantation also seems justified in patients with Huntington's disease and, possibly, in demyelinating disorders. Clinical trials with neurotrophic factors have been initiated in amyotrophic lateral sclerosis, dementia and Huntington's disease, and may later be started in Parkinson's disease and after acute brain insults. However, it remains to be shown if neurotrophic factors can rescue damaged cells in the brain and spinal cord of patients with these disorders.

Trophic factors

The various neurotrophic factors influence a wide range of cell functions in the developing, mature and injured nervous system. Recent studies have provided valuable insights on the receptors that mediate these effects and on the intracellular events that follow the binding of the ligand. Although growth factors were known to be expressed by non-neuronal cells in the targets and pathways of neuronal projections, it is now clear that the neurons themselves can also be a source of these molecules. A better understanding of the mechanisms of action of trophic factors on the survival and differentiation of neurons, coupled with advances in methods for the delivery of these molecules to the nervous system have provided an impetus for exploring their use as aids to the protection and regeneration of the injured nervous system.

Retrograde degenerative changes in the substantia nigra pars compacta following an excitotoxic lesion of the striatum

The retrograde changes induced by an excitotoxic lesion of the striatum (Str) on the neurons in substantia nigra pars compacta (SNc) projecting to the neuron-depleted region were investigated in adult rats. The retrograde tracer Fluoro-Gold (FG) was injected bilaterally into the Str. 2 weeks later, the excitotoxic amino acid ibotenic acid (IA) was injected unilaterally into the same structure. At four different time points after the lesion (1 week and 1, 2 and 3 months, respectively), the size of the FG-labelled cells and number of tyrosine hydroxylase (TH)-positive cells in the SNc were evaluated on the lesioned and control sides. Parallel groups of animals received suspension grafts of fetal striatal tissue into the lesioned striata. At 1 week and 1 month after lesion, there were no changes in cell size, number of TH-positive cells or number of FG-labelled cells expressing TH at the SNc. At 2 and 3 months, however, there was a significant 30% shrinkage of the FG-labelled SNc cells but no evident decrease in TH-positive cell number, or in the expression of the TH protein, on the lesioned side as compared with the non-lesioned control side. Striatal transplants placed into the lesioned Str did not counteract this effect. This finding that an axon-sparing lesion of target cells results in cell shrinkage but no cell loss of the neurons that project to the lesioned area is in line with what has been shown to occur after similar lesions in the cholinergic septohippocampal and basalo-cortical systems.(ABSTRACT TRUNCATED AT 250 WORDS)

Neurotrophic factors: from molecule to man

Recent advances in the understanding of the physiological role of nerve growth factor (NGF) have raised the question of whether neurotrophic factors might have clinical potential in the treatment of neurodegenerative disease or nerve trauma. Although NGF was first characterized as a target-derived survival factor for developing sympathetic and sensory neurons, it is now clear that it plays an important role in the maintenance and regeneration of mature peripheral neurons. However, the highly restricted specificity of NGF for sympathetic neurons, subpopulations of neural-crest-derived sensory neurons, and striatal and basal forebrain cholinergic neurons has, for almost two decades, stimulated the search for other neurotrophic factors that might act on the many classes of neurons that do not respond to NGF. In this article, the biology of the recently discovered NGF-related family of neurotrophic factors and ciliary neurotrophic factor and their receptors are reviewed, especially in the context of the therapeutic potential of these factors in the treatment of neurological disorders of the CNS.

Dopaminergic neurons in rat ventral midbrain express brain-derived neurotrophic factor and neurotrophin-3 mRNAs

Studies of the trophic activities of brain-derived neurotrophic factor and neurotrophin-3 indicate that both molecules support the survival of a number of different embryonic cell types in culture. We have shown that mRNAs for brain-derived neurotrophic factor and neurotrophin-3 are localized to specific ventral mesencephalic regions containing dopaminergic cell bodies, including the substantia nigra and ventral tegmental area. In the present study, in situ hybridization with 35S-labeled cRNA probes for the neurotrophin mRNAs was combined with neurotoxin lesions or with immunocytochemistry for the catecholamine-synthesizing enzyme tyrosine hydroxylase to determine whether the dopaminergic neurons, themselves, synthesize the neurotrophins in adult rat midbrain. Following unilateral destruction of the midbrain dopamine cells with 6-hydroxydopamine, a substantial, but incomplete, depletion of brain-derived neurotrophic factor and neurotrophin-3 mRNA-containing cells was observed in the ipsilateral substantia nigra pars compacta and ventral tegmental area. In other rats, combined in situ hybridization and tyrosine hydroxylase immunocytochemistry demonstrated that the vast majority of the neurotrophin mRNA-containing neurons in the substantia nigra and ventral tegmental area were tyrosine hydroxylase immunoreactive. Of the total population of tyrosine hydroxylase-positive cells, double-labeled neurons constituted 25-50% in the ventral tegmental area and 10-30% in the substantia nigra pars compacta, with the proportion being greater in medial pars compacta. In addition, tyrosine hydroxylase/neurotrophin mRNA coexistence was observed in neurons in other mesencephalic regions including the retrorubral field, interfascicular nucleus, rostral and central linear nuclei, dorsal raphe nucleus, and supramammillary region. The present results demonstrate brain-derived neurotrophic factor and neurotrophin-3 expression by adult midbrain dopamine neurons and support the suggestion that these neurotrophins influence dopamine neurons via autocrine or paracrine mechanisms. These data raise the additional possibility that inappropriate expression of the neurotrophins by dopaminergic neurons could contribute to the neuropathology of disease states such as Parkinson's disease and schizophrenia.

Schwann cells transplanted in the lateral ventricles prevent the functional and anatomical effects of monocular deprivation in the rat

We investigated whether the transplant of Schwann cells prevents the physiological and morphological effects of monocular deprivation in the rat. On the day of eye opening in rats (postnatal day 14), we transplanted Schwann cells in the lateral ventricles and sutured the eyelids of one eye. After 20-30 days, at the end of the critical period for the visual system development, we analyzed the functional properties of visual cortical neurons. Spontaneous discharge, orientation selectivity, and receptive field size of visual cortical neurons in transplanted animals were in the normal range. Transplantation of Schwann cells prevented the detrimental effects of monocular deprivation on ocular dominance and binocularity of cortical neurons. Visual acuity of the deprived eye estimated by visually evoked potentials was also normal. Schwann cells derived from adult animals were as effective as those derived from neonates. The effects of Schwann cells on monocular deprivation were dependent upon the number of cells present in the transplant so that 10(6) Schwann cells were sufficient to prevent the effect of monocular deprivation, whereas 10(5) and 3.3 x 10(5) Schwann cells were ineffective, and 6.3 x 10(5) cells gave variable results. Shrinkage of the deprived lateral geniculate neurons was prevented by a transplant of 10(6) cells. In rats transplanted with hybridoma cells producing an antibody that functionally blocks nerve growth factor (NGF), we found that the effect of cotransplanted Schwann cells on monocular deprivation was partly counteracted. We conclude that transplantation of Schwann cells prevents both functional and anatomical effects of monocular deprivation, presumably acting through the production of NGF. We propose that transplants of Schwann cells could be a promising technique for clinical applications.